The ALIM chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ALIM chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The ALIM stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View ALIM Detailed Price Forecast - CNN Money||View ALIM Detailed Summary - Google Finance|
|View ALIM Detailed Summary - Yahoo! Finance||View ALIM Stock Research & Analysis - Zacks.com|
|View ALIM Trends & Analysis - Trade-Ideas||View ALIM Major Holders - Barrons|
|View ALIM Call Transcripts - NASDAQ||View ALIM Breaking News & Analysis - Seeking Alpha|
|View ALIM Annual Report - CompanySpotlight.com||View ALIM OTC Short Report - OTCShortReport.com|
|View ALIM Fundamentals - TradeKing||View ALIM SEC Filings - Bar Chart|
|View Historical Prices for ALIM - The WSJ||View Performance/Total Return for ALIM - Morningstar|
|View the Analyst Estimates for ALIM - MarketWatch||View the Earnings History for ALIM - CNBC|
|View the ALIM Earnings - StockMarketWatch||View ALIM Buy or Sell Recommendations - MacroAxis|
|View the ALIM Bullish Patterns - American Bulls||View ALIM Short Pain Metrics - ShortPainBot.com|
|View ALIM Stock Mentions - StockTwits||View ALIM Stock Mentions - PennyStockTweets|
|View ALIM Stock Mentions - Twitter||View ALIM Investment Forum News - Investor Hub|
|View ALIM Stock Mentions - Yahoo! Message Board||View ALIM Stock Mentions - Seeking Alpha|
|View Insider Transactions for ALIM - SECform4.com||View Insider Transactions for ALIM - Insider Cow|
|View ALIM Major Holdings Summary - CNBC||View Insider Disclosure for ALIM - OTC Markets|
|View Insider Transactions for ALIM - Yahoo! Finance||View Institutional Holdings for ALIM - NASDAQ|
|View ALIM Stock Insight & Charts - FinViz.com||View ALIM Investment Charts - StockCharts.com|
|View ALIM Stock Overview & Charts - BarChart||View ALIM User Generated Charts - Trading View|
Alimera Announces Expansion of Agreement with Distribution Partner Horus Pharma to Include Marketing ILUVIEN® in Benelux Countries
Posted on Thursday September 12, 2019
Alimera Sciences, Inc. (ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that it has expanded its relationship with Horus Pharma, one of the Company’s current distributors of ILUVIEN® in Europe.
Alimera Sciences Board of Directors Approves Reverse Stock Split and 10b5-1 Stock Purchase Plan for U.S. Executive Management
Posted on Thursday September 05, 2019
Alimera Sciences, Inc. (ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, today announced that its board of directors has approved a proposal to effect a reverse stock split of its common stock. The reverse stock split is expected to result in a higher per share price and a corresponding lower number of total shares issued and outstanding, which should enable Alimera to attain the minimum $1.00 per share bid price requirement for its common stock as required for continued listing on the Nasdaq Global Market. Alimera believes that a reverse stock split can help increase the marketability of its stock to a broader range of potential investors.
Alimera Sciences Launches ILUVIEN® in Germany For Non-Infectious Uveitis Indication
Posted on Tuesday September 03, 2019
Alimera Sciences, Inc. (ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that it will immediately commence the launch of ILUVIEN in Germany for the prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIPU). Following the European Union’s Mutual Recognition Procedure in March 2019, Germany is the second country in Europe in which ILUVIEN is now commercially available to be prescribed to patients suffering from NIPU, a disease with no sustained treatment options.
How Much Of Alimera Sciences, Inc. (NASDAQ:ALIM) Do Institutions Own?
Posted on Tuesday August 06, 2019
Every investor in Alimera Sciences, Inc. (NASDAQ:ALIM) should be aware of the most powerful shareholder groups...